Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice
Abstract Influenza A virus (IAV) is a leading cause of respiratory disease worldwide often resulting in severe morbidity and mortality. We have previously shown that the Bacterial Enzymatic Combinatorial Chemistry (BECC) adjuvants, BECC438 and BECC470, formulated with an influenza virus hemagglutini...
Main Authors: | Robert Haupt, Lauren Baracco, Erin M. Harberts, Madhumathi Loganathan, Lucas J. Kerstetter, Florian Krammer, Lynda Coughlan, Robert K. Ernst, Matthew B. Frieman |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-01-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-27965-x |
Similar Items
-
Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses
by: Lucas J. Kerstetter, et al.
Published: (2021-01-01) -
Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery
by: Kelsey A. Gregg, et al.
Published: (2017-07-01) -
Impact of the TLR4 agonist BECC438 on a novel vaccine formulation against Shigella spp.
by: Ti Lu, et al.
Published: (2023-09-01) -
RIG-I and TLR-7/8 agonists as combination adjuvant shapes unique antibody and cellular vaccine responses to seasonal influenza vaccine
by: Sonia Jangra, et al.
Published: (2022-11-01) -
BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant
by: Deepender Kaushik, et al.
Published: (2020-08-01)